electroCore, Inc. (NASDAQ:ECOR – Get Free Report) CFO Joshua Lev sold 2,166 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $6.18, for a total transaction of $13,385.88. Following the completion of the sale, the chief financial officer directly owned 23,667 shares of the company’s stock, valued at $146,262.06. The trade was a 8.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
electroCore Price Performance
Shares of ECOR opened at $5.60 on Monday. The firm’s 50 day moving average is $5.11 and its 200-day moving average is $5.54. The stock has a market capitalization of $44.80 million, a P/E ratio of -3.27 and a beta of 0.30. electroCore, Inc. has a 12-month low of $4.16 and a 12-month high of $19.49.
electroCore (NASDAQ:ECOR – Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.07). The business had revenue of $8.69 million for the quarter, compared to analyst estimates of $7.84 million. electroCore had a negative net margin of 47.46% and a negative return on equity of 447.87%. electroCore has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that electroCore, Inc. will post -1.49 EPS for the current fiscal year.
Hedge Funds Weigh In On electroCore
Analyst Ratings Changes
Several equities research analysts have recently weighed in on ECOR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of electroCore in a research note on Wednesday, October 8th. Wall Street Zen raised electroCore from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $25.50.
Check Out Our Latest Research Report on electroCore
electroCore Company Profile
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Recommended Stories
- Five stocks we like better than electroCore
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 4 Cold-Weather Stocks to Buy as Winter Spending Heats Up
- How to Calculate Inflation Rate
- Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?
- How to invest in marijuana stocks in 7 steps
- Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
